IONS IONIS PHARMACEUTICALS INC
Price Chart
Executive Summary
Ionis reported positive new data from the open-label extension study (CORE-OLE) of olezarsen for severe hypertriglyceridemia at the National Lipid Association Scientific Sessions. Key findings include mean hepatic fat fraction (HFF) levels returning toward baseline after 24 months, a favorable safety profile, and >90% patient retention. The data update is qualitative and does not include definitive efficacy numbers, making the near-term stock impact limited.
Actionable Insight
The olezarsen data presentation provides incremental but not transformative clinical readout; HFF returning toward baseline may temper enthusiasm for NASH/fatty liver potential. Monitor for more definitive Phase 3 results and regulatory filings. No financial guidance or material agreement was announced, so near-term trading likely driven by broader biotech sentiment rather than this filing.
Key Facts
- Data presented at NLA Scientific Sessions from CORE-OLE study of olezarsen in severe hypertriglyceridemia
- MRI-PDFF results from 53 patients (approx. 25% of substudy) completing 12 months of treatment with 80 mg dose
- Mean HFF levels returning toward baseline after 24 months of treatment
- Less pronounced HFF changes in patients transitioning from 50 mg to 80 mg dose
- Favorable safety profile and >90% patient retention in CORE-OLE
Financial Impact
Not specified
Risk Factors
- HFF returning toward baseline could signal waning efficacy over long-term treatment
- No quantitative efficacy endpoints (e.g., p-values, absolute reductions) disclosed to assess magnitude
- No update on regulatory timeline or commercial outlook for olezarsen
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025050 |
| Document: 0001140361-26-025050-index-headers.html | 0001140361-26-025050 |
| Document: 0001140361-26-025050-index.html | 0001140361-26-025050 |
| Document: 0001140361-26-025050.txt | 0001140361-26-025050 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 16, 2026
4d ago
|
Insider Cluster
| $74.31 $74.12 | ▼ −0.26% | ▼ −1.04% | $74.31 (−0.00%) |
|
Jun 12, 2026
8d ago
|
8-K
| $73.28 $73.96 | ▲ +0.93% | ▼ −0.83% | $74.31 (+1.41%) |
|
Jun 8, 2026
12d ago
|
8-K
| $73.54 $74.58 | ▲ +1.41% | ▲ +1.71% | $74.31 (+1.05%) |
|
May 28, 2026
23d ago
|
8-K
| $77.27 $76.29 | ▼ −1.27% | ▼ −1.51% | $74.31 (−3.83%) |
|
Apr 28, 2026
7w ago
|
Insider Cluster
| $71.50 $74.37 | ▲ +4.01% | ▲ +4.02% | $74.31 (+3.93%) |
|
Apr 21, 2026
8w ago
|
8-K
| $74.71 $74.84 | ▲ +0.17% | ▼ −0.84% | $74.31 (−0.54%) |
|
Apr 16, 2026
9w ago
|
Insider Cluster
| $75.25 $75.71 | ▲ +0.61% | ▼ −0.61% | $74.31 (−1.25%) |
|
Feb 25, 2026
16w ago
|
8-K
| $80.87 $80.34 | ▼ −0.66% | ▼ −0.11% | $74.31 (−8.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access